Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a research report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
Separately, Lake Street Capital decreased their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.
Check Out Our Latest Report on Evogene
Evogene Price Performance
Evogene (NASDAQ:EVGN – Get Free Report) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The firm had revenue of $0.91 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- 3 Small Caps With Big Return Potential
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- 3 Stocks to Consider Buying in October
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- What Are the FAANG Stocks and Are They Good Investments?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.